Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.40
-0.03 (-0.55%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Abeona Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 25.52 | 5.82 | - | 3.5 | 1.41 | 3 | |
Revenue Growth | 6280.00% | - | - | 147.53% | -52.87% | -70.00% |
Cost of Revenue | 35.7 | 30.24 | 34.36 | 32.7 | 29.42 | 38.73 |
Gross Profit | -10.18 | -24.42 | -34.36 | -29.2 | -28 | -35.73 |
Selling, General & Admin | 73.43 | 65.03 | 29.85 | 19 | 17.26 | 21.64 |
Operating Expenses | 73.43 | 65.03 | 29.85 | 19 | 17.26 | 21.64 |
Operating Income | -83.62 | -89.45 | -64.21 | -48.2 | -45.26 | -57.37 |
Interest Expense | -3.31 | -3.74 | -4.21 | -0.42 | -0.74 | -3.66 |
Interest & Investment Income | 5.93 | 5.56 | 4.25 | 2.12 | 0.43 | 0.04 |
Other Non Operating Income (Expenses) | 2.7 | 6.55 | 0.44 | -8.71 | 11.66 | 0.02 |
EBT Excluding Unusual Items | -78.3 | -81.08 | -63.74 | -55.21 | -33.9 | -60.97 |
Impairment of Goodwill | - | - | - | - | - | -32.47 |
Gain (Loss) on Sale of Assets | - | 152.37 | 0 | -0.05 | -0.14 | - |
Asset Writedown | - | - | - | 1.07 | -5.66 | - |
Other Unusual Items | - | - | - | - | - | 8.5 |
Pretax Income | -78.3 | 71.28 | -63.73 | -54.19 | -39.7 | -84.94 |
Income Tax Expense | -15.41 | 0.1 | - | - | - | - |
Net Income | -62.89 | 71.18 | -63.73 | -54.19 | -39.7 | -84.94 |
Preferred Dividends & Other Adjustments | - | - | - | - | 3.78 | - |
Net Income to Common | -62.89 | 71.18 | -63.73 | -54.19 | -43.48 | -84.94 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 56 | 53 | 41 | 21 | 8 | 4 |
Shares Outstanding (Diluted) | 56 | 66 | 41 | 21 | 8 | 4 |
Shares Change | -1.73% | 61.12% | 91.99% | 171.96% | 99.65% | 6.24% |
EPS (Basic) | -1.13 | 1.34 | -1.55 | -2.53 | -5.53 | -21.57 |
EPS (Diluted) | -1.18 | 1.01 | -1.55 | -2.53 | -5.53 | -21.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -81.53 | -84.3 | -58.46 | -37.34 | -43.61 | -69.82 |
Free Cash Flow Per Share | -1.46 | -1.27 | -1.42 | -1.75 | -5.55 | -17.73 |
Gross Margin | -39.90% | - | - | - | - | - |
Operating Margin | -327.64% | -1536.91% | - | -1377.14% | -3200.64% | -1912.33% |
Profit Margin | -246.42% | 1223.08% | - | -1548.23% | -3074.82% | -2831.20% |
Free Cash Flow Margin | -319.46% | -1448.47% | - | -1066.86% | -3084.37% | -2327.20% |
EBITDA | -80.79 | -86.9 | -62.21 | -45.91 | -42.16 | -54.12 |
D&A For EBITDA | 2.83 | 2.55 | 2 | 2.29 | 3.09 | 3.25 |
EBIT | -83.62 | -89.45 | -64.21 | -48.2 | -45.26 | -57.37 |
Effective Tax Rate | - | 0.14% | - | - | - | - |
Revenue as Reported | 25.52 | 5.82 | - | - | - | - |